CAR 90972
Alternative Names: CAR-90972Latest Information Update: 28 Aug 2024
At a glance
- Originator XBiotech
- Class Anti-inflammatories; Anti-ischaemics; Monoclonal antibodies
- Mechanism of Action Interleukin 1 alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Brain injuries
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in Brain injuries in USA (Parenteral)
- 14 Jul 2020 Xbiotech plans a human clinical trial for Brain injuries in USA in 2021 (Parenteral)
- 14 Jul 2020 Preclinical trials in Brain injuries in USA (Parenteral), before July 2020